Although in our cohort we did not perform metastatic tissue biopsies to identify amphicrine prostate cancer histology, reduction in AR alterations in blood on serial monitoring in parallel with less dramatically altered levels of TP53, RB1 and PTEN alterations suggest clonal dynamics consistent with the association of poor patient outcomes with these gene alterations in our study. The gene discussed is AR; the disease is prostate carcinoma.